China SXT Pharmaceuticals Inc

SXTCHealthcare·Drug Manufacturers - Specialty & Generic·China·Nano·NASD·Nov 11 • 1:21 PM ET

2.97+0.09 (3.13%)

2026-11-11 19:21 CET

Market cap

0.30 USD m

Revenue, TTM

1.14 USD m

Net income, TTM

-6.21 USD m

Free cash flow, TTM

-4.02 USD m

EPS diluted, TTM

-64,500.93

P/E

Compare

Price

SXTC against its 20, 50 and 200-day averages

2050200

100.0% under the 52-week high of 8,375,880.00 on 8 Jan 2026. 52-week low 2.71 on 2 Nov 2026. Last 15 sessions, 89.7% high to low

Profile

SXTC

52-week range, 0% of the way up

2.718,375,880

China Sxt Pharmaceuticals, Inc. operates as a holding company, which engages in the research, development, manufacture, marketing, and sales of traditional Chinese medicine pieces (TCMP). Its product categories include directly-oral, after-soaking-oral, fine, and regular TCMP. The firm distributes its product under the Suxuantang brand. The company was founded by Feng Zhou in 2005 and is headquartered in Taizhou, China.

Employees	56
IPO	Jan 04, 2019
Beta	2.00
ATR, 14d	32.56
Rel volume	0.21
Inst own	0.94%

Snapshot

6 groups

Valuation

Index	-
Market Cap	2.04M
Enterprise Value	-25.02M
Income	-6.21M
Sales	1.14M
Book/sh	248057.71
Cash/sh	40.99
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	56
IPO	Jan 04, 2019

Ratios

P/E	-
Forward P/E	-
PEG	-
P/S	1.79
P/B	0.00
P/C	0.07
P/FCF	-
EV/EBITDA	-
EV/Sales	-21.95
Quick Ratio	7.25
Current Ratio	7.93
Debt/Eq	0.04
LT Debt/Eq	0.02
Option/Short	No / Yes

Earnings

EPS (ttm)	-64500.93
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	93.01% 84.85%
Sales past 3/5Y	-16.74% -24.94%
EPS Y/Y TTM	-147.85%
Sales Y/Y TTM	-34.63%
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Ownership

Insider Own	-
Insider Trans	-
Inst Own	0.94%
Inst Trans	-
ROA	-22.00%
ROE	-27.49%
ROIC	-20.41%
Gross Margin	21.85%
Oper. Margin	-630.63%
Profit Margin	-545.24%
SMA20	-32.61%
SMA50	-97.59%
SMA200	-99.97%
Trades	-

Technical

Shs Outstand	0.10M
Shs Float	-
Short Float	-
Short Ratio	0.12
Short Interest	0.03M
52W High	8375880.00 -100.00%
52W Low	2.71 9.60%
Volatility	11.25% 21.01%
ATR (14)	32.56
RSI (14)	27.81
Beta	2.00
Rel Volume	0.21
Avg Volume	228.02K
Volume	29,523

Performance

Perf Week	-0.33%
Perf Month	-61.63%
Perf Quarter	-99.10%
Perf Half Y	-99.98%
Perf YTD	-100.00%
Perf Year	-100.00%
Perf 3Y	-100.00%
Perf 5Y	-100.00%
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	2.88
Price	2.97
Change %	3.13%

Peers

Mkt cap

Ticker	Company	Mkt cap
UPC	Universe Pharmaceuticals INC	8.19M
CPHI	China Pharma Holdings Inc	21.99M
RGC	Regencell Bioscience Holdings Ltd	2.77B
ZYBT	Zhengye Biotechnology Holding Ltd	44.89M
HKPD	Cellyan Biotechnology Co Ltd	4.04M
ZCMD	Zhongchao Inc	4.26M
WOK	Work Medical Technology Group Ltd	5.95M
AHG	Akso Health Group ADR	1.14B
ITOC	iTonic Holdings Ltd	13.60M
ZJYL	Jin Medical International Ltd	741.93M

Ticker

Company

Mkt cap

UPC

Universe Pharmaceuticals INC

8.19M

CPHI

China Pharma Holdings Inc

21.99M

RGC

Regencell Bioscience Holdings Ltd

2.77B

ZYBT

Zhengye Biotechnology Holding Ltd

44.89M

HKPD

Cellyan Biotechnology Co Ltd

4.04M

ZCMD

Zhongchao Inc

4.26M

WOK

Work Medical Technology Group Ltd

5.95M

AHG

Akso Health Group ADR

1.14B

ITOC

iTonic Holdings Ltd

13.60M

ZJYL

Jin Medical International Ltd

741.93M

News

latest 14 of 102

Oct-22-26 08:00AMChina SXT Pharmaceuticals, Inc. Announces Share Consolidation (PR Newswire) -34.25%
Oct-21-26 08:00AMChina SXT Pharmaceuticals Inc Announces Termination of Additional Purchase Right (PR Newswire) +11.79%
Oct-08-26 10:44AMChina SXT Pharmaceuticals Announces $12 Million Registered Direct Offering With Significant Dilution Potential (InvestorsHub) -87.86%
09:22AMChina SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering (PR Newswire)
Aug-05-26 09:00AMChina SXT Pharmaceuticals, Inc. Announces Share Consolidation (GlobeNewswire) -45.57%
Jul-23-26 08:45AMChina SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering (GlobeNewswire) -83.53%
Mar-23-26 09:00AMChina SXT Pharmaceuticals, Inc. Announces Share Re-classification (GlobeNewswire) +5.00%
Jan-30-26 09:00AMChina SXT Pharmaceuticals, Inc. Announces Share Consolidation (GlobeNewswire) -38.00%
Jan-15-26 09:00AMCHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN (GlobeNewswire) +10.18%
Jan-09-26 02:50PMChina SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering (GlobeNewswire) -87.92%
Jan-08-26 09:20AMCHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC AI INSIGHTS INITIATIVE TO OPTIMIZE TRADITIONAL CHINESE MEDICINE PORTFOLIO, ENHANCE MARKET ANALYSIS AND EXPLORE AI-SUPPORTED CLINIC DEPLOYMENT (GlobeNewswire) -37.50%
Mar-17-25 08:30AMChina SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency (GlobeNewswire) -7.09%
Feb-21-25 12:35PMChina SXT Pharmaceuticals, Inc. Announces Share Consolidation (GlobeNewswire) -8.70%
Oct-07-24 04:15PMChina SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency (GlobeNewswire) -10.28%

Key figures

Revenue, TTM	1.14
Net income, TTM	-6.21
EPS diluted, TTM	-64,500.93
EBIT, TTM	-7.18
Free cash flow, TTM	-4.02
Gross margin	21.85%
Operating margin	-630.63%
Net margin	-545.24%
Market cap	0.30
P/E	-
Sales Y/Y, TTM	-34.63%

USD millions. TTM from the statement feed.

Quarterly earnings

actual against estimate

Period	Reported	EPS act	EPS est	EPS rep	Sales act	Sales est	Analysts
No quarterly earnings.

Period

Reported

EPS act

EPS est

EPS rep

Sales act

Sales est

Analysts

No quarterly earnings.

Annual earnings

Period	EPS act	EPS est	EPS rep	Sales act	Sales est
No annual earnings.

Period

EPS act

EPS est

EPS rep

Sales act

Sales est

No annual earnings.

Estimate revisions

last 14 periods

Period	Type	Date	Estimates	Up	Down	Mean	Low	High
No estimate revisions.

Period

Type

Date

Estimates

Down

Mean

Low

High

No estimate revisions.

Estimate history

Period	2017	2018	2019	2020	2021	2022	2023	2024	2025
EPS, annual	10041594.994	13015673.511	-79877720.176	-9166555.439	-264802428.235	-2134054.933	-342923.351	-27853.426	-73038.8
EPS, quarterly
Period
Sales, annual	7.019	7.012	5.162	4.778	2.602	1.972	1.928	1.741	1.138
Period	2017	2018	2019	2020	2021	2022	2023	2024	2025
Sales, quarterly
Period
Shares, annual	0	0	0	0	0	0	0	0.001	0
Period	2017	2018	2019	2020	2021	2022	2023	2024	2025
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY	2023FY	2022FY	2021FY	2020FY	2019FY	2018FY
Total Revenue	1.14	1.14	1.74	1.93	1.97	2.60	4.78	5.16	7.01
Cost of Goods Sold Incl. D&A	0.89	0.89	1.37	1.37	1.55	1.35	1.94	2.46	2.40
Gross Profit	0.25	0.25	0.37	0.55	0.43	1.25	2.84	2.70	4.61
Selling, General and Administrative Excl. Other	7.37	7.37	2.04	2.65	6.03	6.44	4.57	4.04	2.84
Research and Development	-	0.18	0.19	0.18	-	-	-	-	-
Other Operating Expense	0.05	0.05	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Income	-7.18	-7.18	-1.67	-2.09	-5.61	-5.19	-1.73	-1.34	1.77
Interest Expense	0.06	0.06	0.65	0.54	0.48	0.04	1.62	3.35	0.01
Unusual Expense	1.05	1.05	1.01	0.42	0.00	0.00	0.00	5.63	-
Net Income Before Taxes	-6.21	-6.21	-3.30	-3.10	-5.93	-5.41	-2.94	-10.39	1.79
Income Taxes	0.00	0.00	0.00	0.00	0.00	0.33	-0.19	-0.10	0.25
Consolidated Net Income	-6.21	-6.21	-3.30	-3.10	-5.93	-5.74	-2.75	-10.29	1.54
Net Income From Continuing Operations	-6.21	-6.21	-3.30	-3.10	-5.93	-5.74	-2.75	-10.29	1.54
Net Income	-6.21	-6.21	-3.30	-3.10	-5.93	-5.74	-2.75	-10.29	1.54
EPS (Recurring)	-45,655.67	-64,359.54	-21,915.93	-310,158.67	-2,134,065.45	-264,824,330.56	-9,166,415.40	-49,299,152.17	13,015,618.13
EPS (Basic, Before Extraordinaries)	-64,500.93	-73,038.80	-27,853.43	-342,923.35	-2,134,054.93	-264,802,428.23	-9,166,555.44	-79,877,720.18	13,015,673.51
EPS (Diluted)	-64,500.93	-73,038.80	-27,853.43	-342,923.35	-2,134,054.93	-264,802,428.23	-9,166,555.44	-79,877,720.18	13,015,673.51
EBITDA	-7.03	-7.03	-1.59	-1.89	-5.36	-4.87	-1.38	-1.01	1.95
Non-Operating Income (Expense)	2.09	2.09	0.03	-0.04	0.15	-0.18	0.40	-0.07	0.03
Other After Tax Adjustments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Stock Option Compensation Expense	-	5.31	-	-	-	-	-	-	-
Price To Sales Ratio	1.41	1.00	2.04	0.76	0.96	0.11	5.54	2.68	22.08
Gross Margin	21.85	21.85	21.11	28.73	21.62	48.10	59.43	52.37	65.77
Operating Margin	-630.63	-630.63	-96.18	-108.49	-284.40	-199.43	-36.18	-25.98	25.24
Net Margin	-545.24	-545.24	-189.77	-160.67	-301.00	-220.43	-57.52	-199.29	21.95
Shares Outstanding	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Market Capitalization	0.30	0.30	68,675.99	2,445.58	6,485.44	56.88	2,856.62	1,941.73	15,485.44

Income statement, quarterly

Currency USD, millions
Metric	2025S2	2025S1	2024S2	2024S1	2023S2	2023S1	2022S2	2022S1
Total Revenue	0.51	0.63	0.91	0.83	0.99	0.94	0.76	1.21
Cost of Goods Sold Incl. D&A	0.36	0.52	0.68	0.69	0.72	0.75	0.43	1.12
Gross Profit	0.15	0.10	0.23	0.13	0.27	0.19	0.34	0.09
Selling, General and Administrative Excl. Other	0.93	6.44	1.27	0.77	-	9.53	4.79	1.24
Other Operating Expense	0.05	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Income	-0.84	-6.34	-1.04	-0.64	0.27	-9.35	-4.46	-1.15
Interest Expense	0.03	0.03	0.47	0.18	0.21	0.34	0.09	0.38
Unusual Expense	1.05	0.00	1.01	0.00	0.00	-	0.00	0.00
Net Income Before Taxes	0.16	-6.37	-2.50	-0.80	6.60	-9.70	-4.44	-1.49
Income Taxes	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Consolidated Net Income	0.16	-6.37	-2.50	-0.80	6.60	-9.70	-4.44	-1.49
Net Income From Continuing Operations	0.16	-6.37	-2.50	-0.80	6.60	-9.70	-4.44	-1.49
Net Income	0.16	-6.37	-2.50	-0.80	6.60	-9.70	-4.44	-1.49
EPS (Recurring)	7,523.99	-65,868.37	-1,566.65	-23,843.38	285,533.40	-1,856,214.27	-931,981.10	-1,402,348.49
EPS (Basic, Before Extraordinaries)	1,367.04	-65,867.97	-2,180.64	-23,843.51	285,533.62	-1,856,207.07	-931,991.53	-1,402,343.30
EPS (Diluted)	1,367.04	-65,867.97	-2,180.64	-23,843.51	285,533.62	-1,856,207.07	-931,991.53	-1,402,343.30
EBITDA	-0.73	-6.31	-1.02	-0.57	0.37	-9.25	-4.32	-1.04
Non-Operating Income (Expense)	2.09	0.00	0.01	0.02	-0.03	-0.01	0.11	0.04
Price To Earnings Ratio	-	-	-	535.45	-	-	-	-
Price To Sales Ratio	1.41	118.44	19.72	1.30	1.93	0.91	1.64	0.71
Gross Margin	28.74	16.23	25.53	16.25	26.86	19.75	44.09	7.42
Operating Margin	-163.83	-1,011.69	-113.69	-76.95	26.86	-995.02	-583.85	-95.21
Net Margin	32.01	-1,016.46	-274.42	-96.75	667.16	-1,031.96	-581.64	-123.70
Shares Outstanding	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Market Capitalization	0.30	364,327.34	68,675.99	5,701.89	2,445.58	2,812.80	6,485.44	5,563.85

Balance sheet, annual

Currency USD, millions
Metric	2025FY	2024FY	2023FY	2022FY	2021FY	2020FY	2019FY	2018FY	2017FY
Cash & Short Term Investments	28.18	18.13	12.08	17.37	15.57	13.36	7.29	9.29	0.66
Short Term Receivables	3.23	1.30	1.35	1.34	5.53	7.77	10.65	4.93	3.91
Inventories	2.96	1.13	0.81	0.58	1.07	1.38	1.05	1.33	1.49
Other Current Assets	0.14	0.74	-	0.23	0.29	0.18	0.14	0.04	0.04
Total Current Assets	34.51	21.30	14.23	19.52	22.45	22.69	19.13	15.59	6.10
Net Property, Plant & Equipment	0.24	0.36	0.56	1.27	1.59	1.79	1.90	1.81	1.49
Total Investments and Advances	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Intangible Assets	0.01	0.01	0.02	0.03	0.04	0.05	0.05	0.06	0.06
Deferred Tax Assets	-	-	-	-	0.00	0.32	0.11	0.01	0.01
Other Assets	0.00	0.00	8.31	8.74	9.46	9.71	0.51	0.00	0.00
Total Assets	34.75	21.66	23.13	29.55	33.55	34.55	21.70	17.47	7.66
Short Term Debt Incl. Current Port. of LT Debt	0.42	0.77	2.35	3.39	2.05	0.04	6.69	0.23	0.39
Accounts Payable	0.50	1.16	1.28	1.38	1.48	1.46	1.94	1.69	2.41
Income Tax Payable	0.00	1.03	1.05	1.10	1.17	1.16	0.99	1.06	0.87
Other Current Liabilities	3.43	3.05	4.22	8.62	12.43	15.93	2.65	3.34	0.71
Total Current Liabilities	4.35	6.01	8.90	14.50	17.12	18.58	12.26	6.32	4.37
Long Term Debt	0.70	0.21	0.29	0.37	0.00	0.01	0.04	0.00	0.00
Provision for Risks Charges	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Liabilities	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.04	0.00
Total Liabilities	5.05	6.22	9.20	14.86	17.12	18.59	12.30	6.36	4.37
Non-Equity Reserves	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Stock - Carrying Value	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Common Equity	29.71	15.44	13.93	14.69	16.42	15.96	9.40	11.11	3.29
Total Shareholders Equity	29.71	15.44	13.93	14.69	16.42	15.96	9.40	11.11	3.29
Accumulated Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity	29.71	15.44	13.93	14.69	16.42	15.96	9.40	11.11	3.29
Total Liabilities & Stockholders Equity	34.75	21.66	23.13	29.55	33.55	34.55	21.70	17.47	7.66
Book Value Per Share	248,057.71	13,461.70	602,884.56	3,083,670.86	388,107,466.92	49,348,954.21	52,067,750.33	93,926,560.12	27,784,331.13
Tangible Book Value Per Share	248,004.86	13,451.41	602,058.01	3,077,823.23	387,191,540.64	49,207,293.47	51,790,546.08	93,409,935.73	27,271,283.61
Full-Time Employees	56	75	75	78	88	96	97	96	99
Price to Book Ratio	0.00	4,448.00	481.76	441.45	3.46	178.97	206.54	3,904.15	3,904.15
Return on Assets	-22.00	-14.75	-11.76	-18.81	-16.85	-9.77	-52.53	12.25	18.15
Return on Equity	-27.49	-22.50	-21.65	-38.15	-35.42	-21.67	-100.32	21.39	46.22
Return on Invested Capital	-20.41	-21.11	-21.78	-39.42	-34.92	-17.21	-109.01	13.86	36.14
Quick Ratio	7.25	3.35	1.51	1.31	1.25	1.15	1.47	2.26	1.05
Current Ratio	7.93	3.54	1.60	1.35	1.31	1.22	1.56	2.47	1.40

Cash flow, annual

Currency USD, millions
Metric	TTM	2025FY	2024FY	2023FY	2022FY	2021FY	2020FY	2019FY	2018FY
Net Income	-6.21	-6.21	-3.30	-3.10	-5.93	-5.74	-2.75	-10.29	1.54
Depreciation	0.14	0.14	0.08	0.20	0.25	0.32	0.35	0.33	0.18
Other Funds (Non Cash)	4.43	4.43	1.85	1.35	4.19	3.45	2.89	9.05	0.07
Funds from Operations	-1.63	-1.63	-1.37	-1.55	-1.50	-1.63	0.29	-1.01	1.78
Extraordinary Item	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Changes in Working Capital	-2.39	-2.39	-0.97	-0.38	1.42	1.90	-1.61	2.17	-1.41
Income Taxes Payable	0.02	0.02	-0.02	0.00	0.03	-0.03	0.09	-0.02	0.25
Cash from Operating Activities	-4.02	-4.02	-2.35	-1.93	-0.08	0.27	-1.32	1.16	0.37
Capital Expenditures	-1.25	-1.25	-0.00	-0.01	-0.07	-0.06	-0.09	-0.41	-0.61
Net Assets From Acquisitions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	0.00	0.00	0.07	0.00	0.00	0.00	0.00	0.00	-
Purchase or Sale of Investments	0.00	0.00	0.00	0.00	0.00	0.00	-8.85	-5.09	0.00
Purchase of Investments	0.00	0.00	0.00	0.00	0.00	0.00	-8.85	-5.09	0.00
Sale Or Maturity of Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Uses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Sources	0.00	0.00	0.00	0.03	0.06	0.02	3.13	0.00	0.00
Cash from Investing Activities	-1.25	-1.25	0.06	0.03	-0.01	-0.05	-5.81	-5.50	-0.61
Cash Dividends Paid	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Change in Capital Stock	14.29	14.29	2.76	0.00	2.19	3.12	0.00	0.00	0.00
Repurchase of Common Pref Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Common Pref Stock	14.29	14.29	2.76	0.00	2.19	3.12	0.00	0.00	0.00
Proceedsfrom Stock Options	14.29	14.29	2.76	0.00	2.19	3.12	0.00	0.00	0.00
Issuance or Reduction of Debt, Net	0.34	0.14	-0.20	1.31	3.57	2.32	-0.12	6.50	2.38
Change in Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Issuance of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Reduction of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Financing Active Other Cash Flow	0.00	0.00	5.84	-3.93	-2.83	-3.84	12.53	-3.70	6.53
Other Financing Activities Uses	0.00	0.00	-	-3.93	-2.83	-3.84	0.00	-3.70	0.00
Cash from Financing Activities	14.43	14.43	8.40	-2.62	2.94	1.60	12.41	2.80	8.92
Exchange Rate Effect	0.88	0.88	-0.07	-0.77	-1.05	0.39	0.78	-0.47	-0.04
Net Change in Cash	10.05	10.05	6.05	-5.29	1.80	2.21	6.07	-2.00	8.63
Free Cash Flow	-4.02	-4.02	-2.35	-1.94	-0.15	0.21	-1.41	0.75	-0.23
Preferred Dividends (Cash Flow)	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Free Cash Flow	-	-	-	-	-	1.44	-	18.44	-
Deferred Taxes & Investment Tax Credit	-	0.00	0.00	0.00	0.00	0.33	-0.19	-0.10	-0.01

Balance sheet, quarterly

Currency USD, millions
Metric	2025S2	2025S1	2024S2	2024S1	2023S2	2023S1
Cash & Short Term Investments	28.18	21.20	18.13	18.51	12.08	11.47
Short Term Receivables	3.23	3.01	1.30	1.89	1.35	1.28
Inventories	2.96	1.84	1.13	1.59	0.81	0.58
Other Current Assets	0.14	-	0.74	-	-	0.16
Total Current Assets	34.51	26.04	21.30	21.99	14.23	13.50
Net Property, Plant & Equipment	0.24	0.30	0.36	0.44	0.56	1.07
Total Investments and Advances	0.00	0.00	0.00	0.00	0.00	0.00
Intangible Assets	0.01	0.01	0.01	0.02	0.02	0.02
Other Assets	0.00	0.00	0.00	8.55	8.31	0.00
Total Assets	34.75	26.35	21.66	31.00	23.13	14.59
Short Term Debt Incl. Current Port. of LT Debt	0.42	1.04	0.77	2.13	2.35	2.84
Accounts Payable	0.50	0.53	1.16	1.66	1.28	1.32
Income Tax Payable	0.00	1.04	1.03	1.09	1.05	1.04
Other Current Liabilities	3.43	3.35	3.05	10.78	4.22	4.01
Total Current Liabilities	4.35	5.96	6.01	15.66	8.90	9.20
Long Term Debt	0.70	0.16	0.21	0.30	0.29	0.31
Other Liabilities	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	5.05	6.12	6.22	15.96	9.20	9.51
Non-Equity Reserves	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Stock - Carrying Value	0.00	0.00	0.00	0.00	0.00	0.00
Common Equity	29.71	20.23	15.44	15.03	13.93	5.08
Total Shareholders Equity	29.71	20.23	15.44	15.03	13.93	5.08
Accumulated Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity	29.71	20.23	15.44	15.03	13.93	5.08
Total Liabilities & Stockholders Equity	34.75	26.35	21.66	31.00	23.13	14.59
Book Value Per Share	248,057.71	209,262.25	13,461.70	369,477.99	602,884.56	669,543.51
Tangible Book Value Per Share	248,004.86	209,174.00	13,451.41	369,087.27	602,058.01	666,573.59
Price to Book Ratio	0.00	18,006.11	4,448.00	379.24	481.76	191.46
Return on Assets	-22.00	-30.93	-14.75	25.43	-11.76	-76.89
Return on Equity	-27.49	-50.30	-22.50	57.63	-21.65	-141.60
Return on Invested Capital	0.54	-31.23	-15.98	-5.23	46.38	-179.96
Quick Ratio	7.25	4.06	3.35	1.30	1.51	1.40
Current Ratio	7.93	4.37	3.54	1.40	1.60	1.47

Cash flow, quarterly

Currency USD, millions
Metric	2025S2	2025S1	2024S2	2024S1	2023S2	2023S1
Net Income	0.16	-6.37	-2.50	-0.80	6.60	-9.70
Depreciation	0.11	0.03	0.01	0.07	0.10	0.10
Other Funds (Non Cash)	-1.14	5.58	1.72	0.12	-7.35	8.70
Funds from Operations	-0.87	-0.76	-0.76	-0.61	-0.65	-0.90
Extraordinary Item	0.00	0.00	0.00	0.00	0.00	0.00
Changes in Working Capital	-1.40	-0.99	-0.23	-0.75	-0.70	0.32
Income Taxes Payable	0.03	-0.01	-0.02	0.01	0.00	-0.00
Cash from Operating Activities	-2.26	-1.75	-0.99	-1.36	-1.35	-0.58
Capital Expenditures	-1.25	0.00	0.00	0.00	-0.01	0.00
Net Assets From Acquisitions	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Fixed Assets and Businesses	0.00	0.00	0.02	0.04	0.00	0.00
Purchase or Sale of Investments	0.00	0.00	0.00	0.00	0.00	0.00
Purchase of Investments	0.00	0.00	0.00	0.00	0.00	0.00
Sale Or Maturity of Investments	0.00	0.00	0.00	0.00	0.00	0.00
Other Uses	0.92	-0.92	0.00	0.00	0.00	0.00
Other Sources	0.00	0.00	0.00	0.00	0.01	0.02
Cash from Investing Activities	-0.33	-0.92	0.02	0.04	0.01	0.02
Cash Dividends Paid	0.00	0.00	0.00	0.00	0.00	0.00
Preferred Dividends (Cash Flow)	0.00	0.00	0.00	0.00	0.00	0.00
Change in Capital Stock	9.11	5.18	2.76	0.00	0.00	0.00
Repurchase of Common Pref Stock	0.00	0.00	0.00	0.00	0.00	0.00
Sale of Common Pref Stock	9.11	5.18	2.76	0.00	0.00	0.00
Proceedsfrom Stock Options	9.11	5.18	2.76	0.00	0.00	0.00
Issuance or Reduction of Debt, Net	-0.05	0.19	-1.22	1.02	1.19	0.12
Change in Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Issuance of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Reduction of Long Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Net Financing Active Other Cash Flow	0.00	0.00	-0.37	6.21	0.65	-4.58
Other Financing Activities Uses	0.00	0.00	-	-	0.65	-4.58
Cash from Financing Activities	9.06	5.37	1.16	7.24	1.84	-4.46
Exchange Rate Effect	0.51	0.37	-0.58	0.52	0.12	-0.88
Net Change in Cash	6.98	3.07	-0.38	6.44	0.61	-5.90
Free Cash Flow	-2.26	-1.75	-	-	-1.36	-0.58

Revenue breakdown

Advanced TCMP	2024: 258.42K 2025: 49.52K
Others	2024: 40.03K 2025: 7.14K
Regular TCMP	2024: 1.44M 2025: 1.08M
China	2024: 1.74M 2025: 1.14M

Short interest

shares short against float, oldest to newest

Settlement	Of float	Shares short	Float	Avg volume
2026-10-30	0.32%	0.0M	8.8M	221.07K
2026-10-15	8.19%	0.0M	0.1M	101.46K
2026-09-30	6.37%	0.0M	0.0M	12.79K
2026-09-15	6.36%	0.0M	0.0M	12.72K
2026-08-31	1.81%	0.0M	0.0M	10.16K
2026-08-14	2.00%	0.0M	0.0M	7.43K
2026-07-31	18.45%	0.0M	0.0M	2.95K
2026-07-15	0.09%	0.0M	0.0M	8
2026-06-30	0.14%	0.0M	0.0M	9
2026-06-15	0.26%	0.0M	0.0M	10
2026-05-29	0.76%	0.0M	0.0M	6
2026-05-15	0.95%	0.0M	0.0M	7
2026-04-30	0.48%	0.0M	0.0M	29
2026-04-15	1.36%	0.0M	0.0M	34
2026-03-31	10.30%	0.0M	0.0M	39
2026-03-13	5.09%	0.0M	0.0M	36
2026-02-27	8.48%	0.0M	0.0M	35
2026-02-13	11.97%	0.0M	0.0M	33
2026-01-30	8.91%	0.0M	0.0M	11
2026-01-15	4.12%	0.0M	0.0M	6

Option chain

expiry 2026-11-11

Type	Strike	Bid	Ask	Last	IV	Open int	Volume	Delta	Theta	Vega
No option chain for this symbol.

Type

Strike

Bid

Ask

Last

Open int

Volume

Delta

Theta

Vega

No option chain for this symbol.

Latest SEC filings

Filed	Form	Description	Period	Link
2026-10-21	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-10-21	SEC
2026-10-15	SCHEDULE 13G			SEC
2026-10-09	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-10-09	SEC
2026-10-09	424B5			SEC
2026-10-08	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-10-08	SEC
2026-10-08	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-10-08	SEC
2026-09-16	EFFECT	Effectiveness filing by commission order		SEC
2026-08-28	F-3/A			SEC
2026-08-28	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-08-28	SEC
2026-07-24	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-07-24	SEC
2026-07-24	424B5			SEC
2026-07-07	F-3	Registration statement for specified transactions by certain foreign private issuers		SEC
2026-07-06	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-07-06	SEC
2026-07-01	20-F	Registration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.	2026-03-31	SEC
2026-06-01	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-06-01	SEC
2026-06-01	424B5			SEC
2026-05-04	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-05-04	SEC
2026-04-27	3	Initial statement of beneficial ownership of securities	2022-01-31	SEC
2026-04-27	3	Initial statement of beneficial ownership of securities	2017-07-04	SEC
2026-04-27	3	Initial statement of beneficial ownership of securities	2025-01-20	SEC
2026-04-27	3	Initial statement of beneficial ownership of securities	2021-05-22	SEC
2026-04-27	3	Initial statement of beneficial ownership of securities	2022-05-10	SEC
2026-04-27	3	Initial statement of beneficial ownership of securities	2025-01-20	SEC
2026-04-27	3	Initial statement of beneficial ownership of securities	2018-12-31	SEC
2026-04-09	424B5			SEC
2026-04-09	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-04-09	SEC
2026-01-13	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2026-01-13	SEC
2026-01-12	424B5			SEC
2025-12-31	6-K	Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16	2025-09-30	SEC
2025-11-14	EFFECT	Effectiveness filing by commission order		SEC

Insider activity by month

Month	Bought	Buys	Sold	Sells
2026-11	0	0	0	0
2026-10	0	0	0	0
2026-09	0	0	0	0
2026-08	0	0	0	0
2026-07	0	0	0	0
2026-06	0	0	0	0
2026-05	0	0	0	0
2026-04	0	0	0	0
2026-03	0	0	0	0
2026-02	0	0	0	0
2026-01	0	0	0	0
2025-12	0	0	0	0
2025-11	0	0	0	0

Institutional holders

Manager	% owned
UBS Group AG	0.15%
CITIGROUP INC	0.00%
ROYAL BANK OF CANADA	0.00%
Caitong International Asset Management Co., Ltd	0.00%

Funds

Fund	% owned
Fidelity Nasdaq Composite Index Fund	0.04%
Blackstone Alternative Multi-Strategy Fund	0.00%

Fund

% owned

Fidelity Nasdaq Composite Index Fund

0.04%

Blackstone Alternative Multi-Strategy Fund

0.00%

OakChart. SXTC. Cached 15 minutes.

Some panels did not load: ratings, insider.